Related Experiment Video

Updated: Jul 4, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Targeted therapy of renal cell cancer

Piotr J Wysocki1, Jakob Zolnierek, Cezary Szczylik

  • 1University of Medical Sciences, GreatPoland Cancer Center, Department of Cancer Immunology, ul Garbary 15, 61-866 Poznan, Poland.pwysocki@plusnet.pl

Current Opinion in Investigational Drugs (London, England : 2000)
|June 3, 2008
PubMed

Insights

Novel targeted therapies have significantly improved outcomes for advanced renal cell cancer (RCC) patients, offering new hope beyond traditional immunotherapy. Further research is needed to optimize these treatments for all RCC risk groups and settings.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Renal cell cancer (RCC) treatment has seen rapid advancements.
  • The Von Hippel-Lindau (VHL) gene's role in angiogenesis is key to understanding RCC.
  • Cytokine immunotherapy, while established, offers limited benefits and significant toxicity.

Purpose of the Study:

  • To review recent advances in RCC treatment strategies.
  • To highlight the impact of novel targeted therapies.
  • To identify remaining challenges and future research directions in RCC therapy.

Main Methods:

  • Review of phase III clinical trials for novel targeted agents.
  • Analysis of data on progression-free survival and overall survival.
  • Discussion of emerging therapeutic targets and strategies.

Main Results:

  • Targeted agents like temsirolimus, sorafenib, sunitinib, and bevacizumab show significant efficacy in advanced RCC.
  • Temsirolimus demonstrated improved overall survival in high-risk patients.
  • Novel therapies targeting VEGF pathways have improved clinical outcomes.

Conclusions:

  • Targeted therapies represent a significant improvement over traditional immunotherapy for advanced RCC.
  • Further investigation is required for low-risk RCC, optimal sequencing, and adjuvant therapy efficacy.
  • Understanding VHL gene function has opened new avenues for targeted RCC treatment.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...